tetrahydrocannabinol (Also tetrahydrocannabinols) : Related Words Words similar in meaning to tetrahydrocannabinol
- psychoactive drug«
- organic matter«
- dronabinol«
- chemical compound«
- tetrahydrocannabinol«
- cannabinol«
- tetrahydrocannabivarin«
- marinol«
- psychoactive substance«
- substance«
- cannabis«
- psychoactive«
- mind-altering drug«
- parahexyl«
- oral cannabis extract«
- consciousness-altering drug«
- olivetol«
- cannabinoids«
- edible«
- cooh«
- schedule ii«
- cannabis product«
- oral cannabis«
- cannabidiol«
- cannabinoid«
- schedule«
- metabolite«
- spasticity«
- nabiximols«
- multiple sclerosis«
- effect«
- rescheduling«
- cannador«
- psychotropic substance«
- drug«
- effectiveness«
- main isomer«
- capsule«
- narcotic drug«
- urine«
- | doi«
- | issue«
- tetrahydrocannabinolic acid«
- | page«
- thca«
- cannabis extract«
- cervical dystonia«
- quality trial«
- painful spasm«
- raphael mechoulam«
- nabilone«
- reliable conclusion«
- schedule iii drug«
- huntington disease«
- symptom«
- endocannabinoids«
- anandamide«
- schedule iii«
- parkinson disease«
- cannabinoid receptor«
- clinical trial«
- cannabis plant«
- efficacy«
- convention«
- refill«
- medical cannabis«
- controlled substance act«
- tolerance«
- pmid«
- dea«
- insufficient evidence«
- feces«
- | series = handbook«
- vasovagal symptom«
- typical medicinal dosage«
- thca. over time«
- thca biosynthesis«
- thc target receptor«
- thc result«
- thc cannabinoids«
- synthetic cannabinoid agonist«
- svc pharma lp«
- stringent schedule iii. cannabis«
- standardized cannabis sativa extract«
- standardized cannabis extract«
- significant cns symptom«
- rhodes technology«
- receptor efficacy«
- phytocannabinoid family«
- petitioner jon gettman«
- par pharmaceutical company«
- other neurological disorders«
- olivetolic acid react«
- mild antioxidant activity sufficient«
- messenger molecule camp«
- marinol prescription«
- marinol preparation«
- major anticonvulsant«
- low cannabinoid receptor efficacy«
- low cannabinoid receptor density«
- ki=24nm«
- ki=10nm«
- intravenous dronabinol«
- intense intoxication«
- hebrew university pharmacy school«
- harmful uv radiation exposure«
- free thc«
- forensic investigation.-tetrahydrocannabinol«
- epilepsy trial«
- enzyme thc acid synthase«
- drug policy analysis program«
- dronabinol capsule«
- detected.-tetrahydrocannabinol«
- cytochrome p450 enzyme cyp2c9«
- coffee shop | journal = journal«
- cannabinol | journal = cannabinoids | volume«
- cannabidiols«
- bladder complaint«
- bitter acid humulone«
- aromatic terpenoid«
- antiemetic study«
- analytical toxicology | volume«
- alternative thc«
- alcohols.-tetrahydrocannabinol | journal = j. pharm«
- acute psychedelic effect«
- neurology«
- toxicity«
- prescription«
- researcher«
- −)-trans-δ9-tetrahydrocannabinol«
- –)-trans-δ9-tetrahydrocannabinol«
- | date = july«
- yechiel gaoni«
- synthetic dronabinol«
- schedule ii status«
- predetermined dosage«
- partial agonistic activity«
- neurodegenerative disorders«
- natural thc«
- low quality trial«
- endogenous cannabinoid agonist«
- endocannabinoid molecule«
- fda«
- stereochemical variant«
- refractory nausea«
- mr. kleiman«
- lethal human dose«
- female cannabis plant«
- alzheimer«
- discovery«
- smoked cannabis«
- pure isomer«
- mental dependence«
- central pain«
- cannabigerolic acid«
- active secondary metabolite«
- treatment«
- restrictive schedule«
- principal psychoactive constituent«
- mouth spray«
- encapsulated«
- retrograde signaling«
- partial agonist activity«
- cooh.«
- world health organization expert committee«
- specific extract«
- soft gelatin capsule«
- passive exposure«
- dimethylheptylpyran«
- trial«
- mark kleiman«
- cancer cachexia«
- cannabichromene«
- low abuse potential«
- cannabis smoke«
- glassy solid«
- double bond isomer«
- botanical drug«
- research difficult«
- recreational market«
- people accustomed«
- oral fluid«
- equal efficacy«
- cannabinoid receptor cb1«
- american academy«
- δ9-tetrahydrocannabinol«
- lipophilic molecule«
- endogenous agonist«
- solvay pharmaceutical«
- seizure frequency«
- botanical extract«
- maximal effect«
- fatal overdoses«
- plant«
- utility«
- solubility«
- hu-210«
- absorption property«
- therapeutic window«
- treatment arm«
- bladder dysfunction«
- schedule i«
- biosynthetic precursor«
- cannabis smoking«
- geranyl pyrophosphate«
- experimental pharmacology«
- inn«
- postural hypotension«
- glyceride«
- brand names«
- chromatographic technique«
- single death«
- chemical properties«
- overactive bladder«
- abuse«
- oral dos«
- main metabolite«
- people«
- cyp2c19«
- petition«
- inclusion criterion«
- schedule iv«
- result«
- pharmaceutical formulation«
- δ-opioid receptor«
- positive allosteric modulator«
- mouse brain«
- | isbn«
- quality study«
- low potential«
- cb2 receptor«
- single study«
- ikf«
- meta analysis«
- glucuronic acid«
- legal source«
- dyskinesia«
- excitotoxicity«
- aspiration pneumonia«
- psychoactive effect«
- adenylate cyclase«
- brain«
- systemic effect«
- illicit traffic«
- human fatality«
- levodopa«
- dea.«
- single convention«
- drug dependence«
- article«
- motor coordination«
- pain«
- objective measure«
- low solubility«
- person«
- insufficient data«
- cyp3a4«
- testing program«
- | pmid«
- suicidal ideation«
- downregulation«
- stereoisomers«
- who.«
- neuropathic pain«
- scrip«
- aan«
- tourette syndrome«
- final rule«
- sesame oil«
- human study«
- adipose tissue«
- hallucinogen«
- hallucinogenic drug«
- psychedelic drug«
- psychodelic drug«
- designer drug«
- euphoriant«
- phencyclidine hydrochloride«
- psilocin«
- phencyclidine«
- salvinorin«
- psilocybin«
- lysergic acid diethylamide«
- mescaline«
- peyote«
- angel dust«
- 1045th meeting«
- 10.1093/jat/34.4.196«
- 33rd meeting«
- 2-ag«
- 2-arachidonoylglycerol«
